Barclays’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-100
| Closed | -$15K | – | 4223 |
|
|
2021
Q3 | $15K | Buy |
+100
| New | +$14.6K | ﹤0.01% | 4446 |
|
|
2020
Q4 | – | Sell |
-31,200
| Closed | -$3.57M | – | 4938 |
|
|
2020
Q3 | $3.57M | Hold |
31,200
| – | – | ﹤0.01% | 1638 |
|
|
2020
Q2 | $3.56M | Sell |
31,200
-39,500
| -56% | -$4.19M | ﹤0.01% | 1634 |
|
|
2020
Q1 | $5.68M | Buy |
70,700
+35,700
| +102% | +$3.7M | ﹤0.01% | 1369 |
|
|
2019
Q4 | $3.74M | Sell |
35,000
-1,000
| -3% | -$104K | ﹤0.01% | 2328 |
|
|
2019
Q3 | $3.85M | Buy |
36,000
+33,100
| +1,141% | +$3.4M | ﹤0.01% | 2089 |
|
|
2019
Q2 | $295K | Sell |
2,900
-4,000
| -58% | -$384K | ﹤0.01% | 4773 |
|
|
2019
Q1 | $620K | Sell |
6,900
-6,800
| -50% | -$589K | ﹤0.01% | 3914 |
|
|
2018
Q4 | $1.14M | Buy |
13,700
+5,000
| +57% | +$469K | ﹤0.01% | 2973 |
|
|
2018
Q3 | $939K | Sell |
8,700
-12,800
| -60% | -$1.4M | ﹤0.01% | 3687 |
|
|
2018
Q2 | $2.36M | Buy |
21,500
+14,500
| +207% | +$1.51M | ﹤0.01% | 2414 |
|
|
2018
Q1 | $702K | Sell |
7,000
-3,700
| -35% | -$379K | ﹤0.01% | 3605 |
|
|
2017
Q4 | $1.05M | Sell |
10,700
-4,700
| -31% | -$446K | ﹤0.01% | 3069 |
|
|
2017
Q3 | $1.44M | Buy |
+15,400
| New | +$1.63M | ﹤0.01% | 2654 |
|
|
2017
Q2 | – | Sell |
-300
| Closed | -$29K | – | 6686 |
|
|
2017
Q1 | $29K | Sell |
300
-11,800
| -98% | -$1.12M | ﹤0.01% | 5619 |
|
|
2016
Q4 | $1.11M | Sell |
12,100
-13,700
| -53% | -$1.18M | ﹤0.01% | 2641 |
|
|
2016
Q3 | $2.18M | Buy |
25,800
+13,400
| +108% | +$1.13M | ﹤0.01% | 1933 |
|
|
2016
Q2 | $1.01M | Sell |
12,400
-3,200
| -21% | -$244K | ﹤0.01% | 2605 |
|
|
2016
Q1 | $1.11M | Buy |
15,600
+6,500
| +71% | +$436K | ﹤0.01% | 2434 |
|
|
2015
Q4 | $646K | Sell |
9,100
-500
| -5% | -$33.6K | ﹤0.01% | 2990 |
|
|
2015
Q3 | $586K | Sell |
9,600
-10,200
| -52% | -$713K | ﹤0.01% | 3216 |
|
|
2015
Q2 | $1.43M | Buy |
19,800
+12,300
| +164% | +$908K | ﹤0.01% | 2547 |
|
|
2015
Q1 | $570K | Sell |
7,500
-29,900
| -80% | -$2.14M | ﹤0.01% | 3494 |
|
|
2014
Q4 | $2.51M | Buy |
37,400
+2,600
| +7% | +$164K | ﹤0.01% | 2320 |
|
|
2014
Q3 | $2.09M | Sell |
34,800
-148,600
| -81% | -$9.16M | ﹤0.01% | 2625 |
|
|
2014
Q2 | $10.6M | Sell |
183,400
-1,300
| -0.7% | -$76.1K | 0.01% | 1108 |
|
|
2014
Q1 | $10.5M | Buy |
184,700
+145,200
| +368% | +$7.78M | 0.01% | 1098 |
|
|
2013
Q4 | $2.09M | Buy |
39,500
+3,200
| +9% | +$190K | ﹤0.01% | 2622 |
|
|
2013
Q3 | $2.21M | Buy |
36,300
+19,900
| +121% | +$1.19M | ﹤0.01% | 2448 |
|
|
2013
Q2 | $994K | Buy |
+16,400
| New | +$977K | ﹤0.01% | 3362 |
|
Other funds holding DGX
VCM
VPM
EIG
Barclays's DGX Position: Q1 2026 in Review
Barclays increased its Quest Diagnostics (DGX) stake by 70% in Q1 2026, buying an estimated $45.1M and bringing the position to 565,470 shares worth $111M. The position accounts for 0.03% of the portfolio, ranked #460.
Barclays first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Barclays held 565,470 shares of Quest Diagnostics worth $111M as of Q1 2026.
- Barclays bought 232,168 Quest Diagnostics shares in Q1 2026, an estimated $45.1M.
- Quest Diagnostics made up 0.03% of Barclays's portfolio in Q1 2026, its #460 holding.
- Barclays first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
- 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.